<DOC>
	<DOCNO>NCT01508455</DOCNO>
	<brief_summary>The primary objective study characterize safety , efficacy Dexmedetomidine ( DEX ) administer intravenous ( IV ) load dose follow continuous IV infusion preterm subject , age ≥ 28 week &lt; 36 week gestational age .</brief_summary>
	<brief_title>Open-Label , Safety , Efficacy Study Dexmedetomidine Preterm Subjects Ages ≥28 Weeks &lt; 36 Weeks Gestational Age</brief_title>
	<detailed_description />
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 . Initially intubate mechanically ventilated pediatric subject intensive care set anticipated require least 6 hour continuous IV sedation . 2 . Age : subject must fit follow age range screening : Preterm subject ≥28 week &lt; 36 week , gestational age ; Note : Gestational age ( week ) calculate follow : time elapse first day last menstrual period day enrollment . 3 . Weight : subject 's weight time enrollment must &gt; 1000 g. 4 . Subject 's parent ( ) legal guardian ( ) has/have voluntarily sign date informed consent document approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) . 1 . Neonate subject neurological condition prohibit evaluation sedation : Diminished consciousness increase intracranial pressure . The presence catastrophic brain injury severe mental disorder would make response sedatives unpredictable and/or measurement NPASS unreliable . Subjects immobility neuromuscular disease continuous infusion neuromuscular blocking ( NMB ) agent . 2 . Subjects second degree third degree heart block unless subject pacemaker pacing wire situ . Note : If subject 's statuspost Cardio Pulmonary Bypass ( CPB ) manage without pace wire situ , subject must suspect second degree third degree heart block time DEX administration . 3 . HR &lt; 120 bpm prior initiation DEX . 4 . Exposure investigational drug within 30 day prior DEX administration . 5 . Previous exposure DEX part investigational study . 6 . In subject exutero less 72 hour , maternal history polysubstance drug abuse , base upon Investigator 's clinical judgment . 7 . At discretion Investigator , subject risk DEX treatment expect exceed benefit . 8 . Subjects know allergy contraindication fentanyl , morphine , MDZ , DEX , α2 agonist . 9 . Requirement medication DEX , MDZ , morphine , fentanyl sedation pain control . 10 . Screening ALT level &gt; 115 U/L .</criteria>
	<gender>All</gender>
	<minimum_age>28 Weeks</minimum_age>
	<maximum_age>36 Weeks</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>